Cancer Institute– A national cancer institute
designated cancer center

Philip W. Lavori

Back to Profile

Publication Details

  • Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.

    Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Circulation. 2004; 110 (11): 1437-42

    Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent.

    PubMedID: 15337700

Stanford Medicine Resources:

Footer Links: